-
The World Environment Day, a United Nations event, focuses this year on air pollution, an environmental problem that kills some 7 million people every year worldwide.
-
From 1 to 5 June 2019 the EAACI Congress greeted once again with a "Welcome to Lisbon"! This year's event centered primarily on precision medicine; with many innovative concepts and ideas on the future of allergology throughout the congress' numerous sessions.
-
At the end of this year's Congress of the American Society of Oncology (ASCO) in Chicago, results of the primary endpoint analysis of the CLL14 study were presented for the first time. These are results that will change current medical approaches.
-
The PD-1 inhibitor pembrolizumab (Keytruda) significantly improves the 5-year survival rates of patients with non-small cell lung cancer (NSCLC). The effect was particularly good in patients with high PD-L1 expression.
-
The non-steroidal antiandrogen ensalutamide plus standard therapy increased the 3-year survival rate in men with mHSPC to 80% compared to 72% achieved with other non-steroidal antiandrogens. This was confirmed by an interim analysis of the phase III ENZAMET study.
-
In about 50% of metastasized melanomas, a BRAF mutation is found, in these cases, targeted therapy can be applied. But immunotherapeutics have also revolutionized melanoma treatment in the last ten years.
-
For the first time, a biomarker-based therapy prolonged overall survival in premenopausal women with breast cancer. In the MONALEESA 7 Phase III study, a joint Ribociclib/endocrine therapy reduced death risk by 29%.
-
Anal carcinoma is closely associated with infection by human papillomaviruses. An HPV vaccination, therefore, offers a good possibility for prevention.
-
There are many reasons for physicians to become involved in social media, and various studies have now also proven the benefits. Nonetheless, risks must also be taken into account, as we learned at ASCO 2019.
-
The lowest dose of oxaliplatin/capecitabine tested was as effective in elderly and frail patients with advanced gastroesophageal carcinoma as the highest dose investigated.
-
CAR-T cell therapy is highly controversial in research. The two most important side effects, cytokine release syndrome, and neurotoxicities were presented and discussed in a symposium.
-
Cancer-specific DNA repair defects are common in malignant tissue, but they provide an opportunity for therapeutic attack.
-
For the first time, a biomarker-based therapeutic approach in pancreatic cancer has been able to prolong progression-free survival (PFS).
-
The European Academy of Andrology (EAA) has issued a new guideline with 15 recommendations for managing these clinical cases.
-
A recent study on mice concludes that targeted ultrasound could be an effective, noninvasive and drug-free way to increase insulin levels in people with type 2 diabetes.
-
For osteoporosis, there is still a lot of catching up needed throughout Europe: some 85% of women with osteoporosis-related bone fractures do not receive adequate treatment to prevent the recurrence of such fractures.
-
A recent retrospective observational study in diabetic men with prostate cancer suggests that poor glycemic control before radical prostatectomy increases the risk of later progression, including metastasis.
-
HIV-negative men who have sex with men (MSM), who use PrEP, are significantly more likely to have other sexually transmitted diseases.
-
Researchers have tested another antibody against HIV that suppressed the further proliferation of the virus in infected individuals.
-
Acellular vaccines against Bordetella pertussis protect about 75% of vaccinated children between the ages of five and nine years. Approximately 65% of these children are vaccinated for five years. However, it is not possible to eradicate the disease.
